Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Adverse outcomes and high incidence of therapy-related neoplasms in patients with the t(16;21)/RUNX1::RUNX1T3 fusion.

Leukemia & lymphoma - 1 Feb 2026

Guo Dongmei, Wang Cui, Yao Jingya, Chen Long, Nie Yanbo, Liu Enbin, Tian Xin, Hou Xiaoju, Yang Shaobin, Lin Yani

Abstract excerpt

The t(16;21)(q24;q22) translocation creates the RUNX1::RUNX1T3 (also known as CBFA2T3, MTG16) fusion gene, representing a rare but clinically significant subtype of myeloid neoplasms. This comprehensive study presents detailed clinical, immunophenotypic, cytogenetic, and molecular data from 10 new cases while integrating findings from 35 previously reported cases. Patients showed a median age of 48 years with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromosomes, Human, Pair 21
Share to Core Binding Factor Alpha 2 Subunit

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunophenotyping

Share to Incidence

Share to Oncogene Proteins, Fusion

Share to Prognosis

Share to Translocation, Genetic

Share to Young Adult

Source

Identifiers

PMID: 41424335
DOI: 10.1080/10428194.2025.2603553

Genes

RUNX1
ASXL1
CBFA2T3
CD19
JAK2
NRAS
RUNX1T1
TET2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Adverse outcomes and high incidence of therapy-related neoplasms in patients with the t(16;21)/RUNX1::RUNX1T3 fusion.PMID 41424335Read ↗

Rare and novel RUNX1 fusions in myeloid neoplasms: A single-institute experience.Semantic proximity Read ↗

High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome.Semantic proximity Read ↗

RUNX1 mutation associated with clonal evolution in relapsed pediatric acute myeloid leukemia with t(16;21)(p11;q22).Semantic proximity Read ↗

Cytogenetic and Molecular Analysis of a "Double-Hit" RUNX1 Including a RUNX1 p.Trp279* and a Cryptic Novel t(6;21)(q25;q22)/RUNX1::ARID1B in Acute Myeloid Leukemia.Semantic proximity Read ↗

AML with RUNX1::RUNX1T1 Cooperating two Mutations Relapsed Quickly after Achieving CR.Semantic proximity Read ↗

Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations.Semantic proximity Read ↗

Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcriptsSemantic proximity Read ↗

Molecular characteristic of acute leukemias with t(16;21)/FUS-ERG.Semantic proximity Read ↗

Acute myeloid leukemia with rare recurring translocations—an overview of the entities included in the international consensus classificationSemantic proximity Read ↗

A novel t(X;21)(p11.4;q22.12) translocation adds to the role of BCOR and RUNX1 in myelodysplastic syndromes and acute myeloid leukemias.Semantic proximity Read ↗

Comprehensive Mutation Profile in Acute Myeloid Leukemia Patients with RUNX1-RUNX1T1 or CBFB-MYH11 FusionsSemantic proximity Read ↗

Cytogenetic analysis of acute myeloid leukemia with t(8;21) from a tertiary care center in India with correlation between clinicopathologic characteristics and molecular analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.